Dynamiris Inc., a Queen’s spinoff company developing a fast, objective, and low-cost AI-enhanced eye tracking system, is working to advance technology that could support earlier detection and diagnosis of neurological conditions. Janis Kan, a Queen’s neuroscience PhD graduate and co-founder of Dynamiris, is helping guide the development of the company’s product, SimplyView, with patients and end users in mind.
The product, based on the work of Queen’s researcher Doug Munoz (Biomedical and Molecular Sciences) and his team, involves patients watching video clips while a camera captures their eye movements. The software algorithm then analyzes these movements, measuring over 100 different variables related to pupil size, blink rate, and gaze direction. This data is used to identify specific patterns and anomalies associated with neurological disorders, such as Parkinson's disease.
Parkinson’s disease is a progressive disorder of the nervous system, particularly affecting cells of the brain that control movement. As with many neurodegenerative diseases, early detection is important for diagnosis, treatment, and quality of life.
“Despite its prevalence, there is no definitive test for Parkinson's, leading to delayed diagnoses and treatment,” says Dr. Kan. The technology developed from Dr. Munoz’s research aims to provide clinicians with additional information that could support the identification and understanding of neurological disorders.
Dynamiris continues to advance its technology by combining decades of eye movement research with AI and software development. The company is exploring how this approach could contribute to faster, more objective assessment of neurological conditions and, ultimately, support better outcomes for patients and their families.
To learn more, visit the Dynamiris Inc. website.